Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Pfizer And Medivation Initiate Phase 3 Trial Of Dimebon In Patients With Huntington Disease
Pfizer Inc (NYSE: PFE) and Medivation, Inc. (NASDAQ: MDVN) announced the initiation of a Phase 3 trial of the investigational drug dimebon (latrepirdine) in patients with Huntington disease. The international safety and efficacy trial, known as HORIZON, is designed to evaluate the potential benefits of dimebon on cognition (thinking and memory) in patients with Huntington disease. The companies also announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to dimebon for the treatment of Huntington disease. Buy arimidex to treat cancer.

Smoking Bans Do Not Cause Job Losses In Bars And Restaurants
New research suggests that exempting bars from community smoking bans makes no economic difference in terms of preserving bar employment, and that even the most comprehensive clean indoor air policies do not lead to a reduction in hospitality jobs.

generic viagra online


News of the day
Genomic Medicine Institute Adds Seven Additional Illumina Genome Analyzers To Expand Capacity For Asian 100 Genome Project
Illumina (NASDAQ:ILMN) announced that the Genomic Medicine Institute (GMI) at Seoul National University College of Medicine in Korea, purchased seven additional Illumina Genome AnalyzerIIx sequencing systems, expanding the capacity of their recently established Asian Genome Center to 10 Illumina sequencing systems.
Oncology

Lethality Of H1N1 Influenza Virus Increasing According To Latest Analysis Of Virus Peptide Genomic Data

An analysis of the latest peptide genomic data for the H1N1 influenza virus indicates that the current global outbreak of H1N1 is increasing in its capacity for lethality. The new sequence data on PubMed of the past two weeks through June 10, 2009 showed an increase in the Replikin Count* of the Replikin Lethality Gene in the pB1 genomic area from a mean of 2+/-0.2 in 2008 to a mean of 3.2+/-3.7 in 2009 (p


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009